Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
Postmenopausal women with metastatic, hormone receptor-positive breast cancer may now be treated with everolimus (Afinitor) in combination with exemestane (Aromasin), following FDA’s recent approval of the tablet medicine.
FDA approves pertuzumab (Perjeta) for use in treating HER2 positive metastatic breast cancer when combined with trastuzumab (Herceptin), an anti-HER2 medicine that targets a different part of the HER2 protein, and docetaxel (Taxotere), a type ofchemotherapy.
NEW YORK (Reuters Health) - Older women who eat a lot of starchy and sweet carbohydrates may be at increased risk of a less common but deadlier form of breast cancer, a new study suggests.
HONG KONG (Reuters) - Breast cancer cells can shut down a powerful immune response in the body, which allows the disease to spread to the patient's bones, researchers in Australia reported on Monday.
NEW YORK (Reuters Health) - Women who were in the workforce before a breast cancer diagnosis often get back to their normal job routine after treatment, a study of Swedish women finds.
(Reuters) - The U.S. Food and Drug Administration said on Friday it has approved Novartis AG's drug Afinitor to treat women with a certain type of breast cancer.
Young age--under 40 years old--when diagnosed with breast cancer does not by itself predict a worse outcome.
NEW YORK (Reuters Health) - Women under 40 who use estrogen to ease menopause symptoms after having their ovaries removed do not have an increased risk of breast cancer, according to a new study.
NEW YORK (Reuters Health) - A new study is fueling hopes that metformin, a cheap and relatively safe diabetes drug, might have cancer-fighting properties.
CHICAGO (Reuters) - Not too long ago, knowing the organ where a cancer first takes hold was generally all a doctor needed to determine what treatments to use. Not anymore.
Advances in understanding cancer at the molecular level mean doctors can better select the drugs that will most help individual patients. To do so, they must identify which genetic mutations are driving the growth of a patient's tumor, and that shift is making their work much harder.